Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.33 |
| ▸ | BHMT | Q93088 | 1/20 | 0.33 |
| ▸ | GMNN | O75496 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17030087 | 0.83 | BHMT (0.45) | CYP2C19CYP2D6HIF1ABHMTGMNN | |
| SCHEMBL17030085 | 0.83 | LMNA (0.42) | CYP2C19MTNR1AMTNR1BBHMTMAPT | |
| SCHEMBL17072562 | 0.79 | NOS3 (0.31) | — | |
| SCHEMBL17030036 | 0.76 | CYP2C19 (0.37) | CYP2C19CYP2D6HIF1ABHMTGMNN | |
| SCHEMBL17030203 | 0.75 | MTNR1A (0.33) | MTNR1AMTNR1B | |
| SCHEMBL17224709 | 0.75 | ITGB3 (0.48) | MAPTITGB3ITGA2B | |
| SCHEMBL17224692 | 0.75 | ITGB3 (0.48) | MAPTITGB3ITGA2B | |
| SCHEMBL5170315 | 0.75 | ITGB3 (0.48) | MAPTITGB3ITGA2B | |
| SCHEMBL22840759 | 0.74 | — | — | |
| SCHEMBL17030075 | 0.74 | TDP1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150250217-A1 | SALTY TASTE-ENHANCING AGENT AND MANUFACTURING METHOD THEREFOR, AND SALTY TASTE-ENHANCING METHOD | NISSAN FOODS HOLDINGS CO., LTD. (JP) | 2015-09-10 | — | — | US | disclosed |
| EP-2910130-A1 | SALTY TASTE-ENHANCING AGENT AND MANUFACTURING METHOD THEREFOR, AND SALTY TASTE-ENHANCING METHOD | Nissin Foods Holdings Co., Ltd. (JP) | 2015-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150250217-A1 | SALTY TASTE-ENHANCING AGENT AND MANUFACTURING METHOD THEREFOR, AND SALTY TASTE-ENHANCING METHOD | TAS2R8, TAS2R13, TAS2R38 | CYP2C19 4714/4885CYP2D6 4738/4885HIF1A 2719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.